Life Sciences

  • June 13, 2022

    Justices Spurn Insys Exec's Appeal In Landmark Opioid Case

    The U.S. Supreme Court said Monday it would not hear an appeal by John Kapoor, the founder of Insys Therapeutics Inc., challenging his conviction for orchestrating a scheme to bribe doctors to prescribe a powerful opioid spray.

  • June 10, 2022

    US Taking Long View On Reshaping WTO As Summit Opens

    As World Trade Organization members huddle in Geneva this week for a long-awaited ministerial summit, the Biden administration made clear that while it hopes to reach agreement on a number of pressing issues, it sees the meeting as a launchpad for future work.

  • June 10, 2022

    Opioid Judge Disavows 'Unfair' Atty Fees But Still Draws Fire

    The federal judge steering multidistrict opioid litigation revisited a controversial order regarding discovery and attorney fees, but counsel for local governments said Friday that the purported clarification doesn't adequately address a high-profile call for Sixth Circuit intervention.

  • June 10, 2022

    GoodRx Investors' Claims Over IPO Get Axed For Good

    A California judge gave a final toss to investor litigation accusing GoodRx of inflating the health care technology company's initial public offering stock price by hiding news of a rival Amazon program in the works, saying Thursday a revised complaint still lacked facts showing the defendants knew of the competitor's plans.

  • June 10, 2022

    9th Circ. Mulls If Valid Patents Moot FCA Suit Against Bausch

    A Ninth Circuit judge considering whistleblower allegations that Bausch Health fraudulently obtained a patent to prolong its monopoly on colitis drug Apriso pressed the plaintiff's attorney Friday on whether other valid patents also protected the drug, commenting, "If that's the case, then you don't have a False Claims Act claim."

  • June 10, 2022

    Fed. Circ. Eyes Eligibility Of Stanford's Transplant Testing IP

    Two Federal Circuit judges did not seem fully convinced Friday that three Stanford University patents licensed to CareDx Inc., developer of commercial tests for kidney transplant rejections, are valid under the U.S. Supreme Court's landmark Alice ruling. 

  • June 10, 2022

    States Get $853K In Pared Down Shkreli Antitrust Case Fees

    A New York federal judge signed off Friday on $853,440.80 in attorney fees for four of the states that successfully sued "pharma bro" Martin Shkreli for an anti-competitive scheme safeguarding a 40-fold price increase for a lifesaving drug, a significant reduction on the more than $2 million initially sought.

  • June 10, 2022

    Bayer Notches 3rd Roundup Trial Win With Missouri Verdict

    Lawyers for German chemical conglomerate Bayer were able to convince a majority of jurors in a Missouri county court that years of using Monsanto's Roundup weedkiller did not cause a man to develop non-Hodgkin's lymphoma, following a monthlong trial.

  • June 10, 2022

    Balwani Can't Get Jury Edge Over Lost Theranos Database

    A California federal judge finalized jury instructions in former Theranos executive Ramesh "Sunny" Balwani's criminal fraud trial on Friday, refusing his request to instruct jurors that they can infer that inaccessible Theranos patient-testing data in a missing database is unfavorable to the government's case.

  • June 10, 2022

    Trader Pleads Guilty In Biotech Co. Stock Spoofing Scheme

    An investor in the medical technology company Arrayit Corp. pleaded guilty to securities fraud in California federal court Thursday, admitting his role in a scheme to manipulate the prices of its stock through the spread of false and misleading information about the company, according to hearing minutes.

  • June 10, 2022

    Sens. Urge Vidal To Block Drug Patent 'Thickets' Early

    A sextet of bipartisan senators has asked the U.S. Patent and Trademark Office director to make sure that drugs aren't getting more patent protection than their inventiveness calls for by taking on so-called patent thickets at the examination stage.

  • June 10, 2022

    Zymeworks Takes Poison Pill To Block Hostile Bid

    Cancer drug developer Zymeworks Inc. on Friday announced a poison pill strategy to block a $773 million hostile takeover bid by All Blue Capital, saying it substantially undervalued the company.

  • June 10, 2022

    NYC Teachers Want Judge Off Vax Case Due To Pfizer Stock

    Challengers to New York City's vaccine order want the federal judge overseeing their case disqualified, after discovering she held up to $100,000 in Pfizer stock in 2020.

  • June 10, 2022

    Del. Court Denies Ex-CEO GenapSys Committee Access

    The former CEO of gene sequencing company GenapSys Inc. lost his bid for more access to the work of the special committee that is considering putting the company into bankruptcy, while the committee got a warning from Delaware Chancery Court to be transparent and "tread carefully going forward."

  • June 10, 2022

    Rising Star: Baker McKenzie's Khelin Aiken

    Khelin Aiken of Baker McKenzie is helping Johnson & Johnson spin off its consumer health business — which made $15 billion last year — earning her a spot among the life sciences attorneys under age 40 honored by Law360 as Rising Stars.

  • June 10, 2022

    Hogan Lovells Adds Foley Hoag M&A Co-Chair In Boston

    A Boston mergers and acquisitions attorney has joined Hogan Lovells' corporate and finance practice after two decades at Foley Hoag LLP, where he was co-chair of the M&A practice.

  • June 09, 2022

    IP Forecast: '60 Seconds' Car Copyright Saga Rolls Into LA

    A federal judge in Los Angeles is scheduled next week to hold a hearing on whether the Ford Mustang featured in the movie “Gone in 60 Seconds” starring actor Nicolas Cage is a copyright-protected character like the Batmobile. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.

  • June 09, 2022

    Balwani Rests After Testimony On Lost Theranos Database

    Ex-Theranos executive Ramesh "Sunny" Balwani rested his defense case in a monthslong criminal fraud trial Thursday after a daylong examination of Balwani's expert witness who testified over objections that the government could have recovered a missing Theranos database, which Balwani claims contains exculpatory patient-testing data.

  • June 09, 2022

    FTC Eyes Drugmaker Rebates Boosting Higher Cost Drugs

    Bolstered by a newly full roster, the Federal Trade Commission teed up one of its most ambitious open meetings in months Thursday that includes a plan to issue a new policy statement that would target rebates drugmakers pay to get their therapies prescription preference over "lower-cost" alternatives.

  • June 09, 2022

    Shipping Co. Wants Suit Over $200M Accident Award Nixed

    A Geneva-headquartered shipping company accused of not paying nearly $200 million awarded in arbitration proceedings over a container ship that caught fire 10 years ago has urged a Louisiana federal court to toss the shipowner's suit seeking to enforce the award.

  • June 09, 2022

    FDA Answers Hair Loss Drug Petition, Group Drops Suit

    A nonprofit suing the U.S. Food and Drug Administration for allegedly taking too long to decide whether to pull Merck's prescription hair loss drug from the market said on Thursday it was dropping its suit now that the agency has made its decision, according to the group's attorney.

  • June 09, 2022

    Jury Clears Reckitt Benckiser In Trade Secret, Fraud Trial

    A New Jersey federal jury has cleared health- and hygiene-related consumer goods maker Reckitt Benckiser of fraud and trade secret misappropriation claims in a suit from Absorption Pharmaceuticals over a premature ejaculation treatment.

  • June 09, 2022

    FTC Judge Says Lives At Stake In Cancer Test Deal Challenge

    Federal Trade Commission staffers pressed their bid to block Illumina's $8 billion reacquisition of cancer testing outfit Grail during closing arguments, as the agency's administrative law judge questioned whether getting the case wrong could cost lives.

  • June 09, 2022

    Ex-Illumina CPA Ducks Prison After Insider-Trading Testimony

    A Manhattan federal judge on Thursday allowed a former Illumina Inc. accountant to avoid prison after she testified to passing secret earnings information about the California gene tech company to a San Diego speculator currently in prison for insider trading.

  • June 09, 2022

    Reed Smith Litigator Joins Jackson Walker In Houston

    Jackson Walker LLP has added a Reed Smith LLP litigator with experience representing clients facing class actions and multidistrict litigation to its trial and appellate practice in Houston.

Expert Analysis

  • Collaborative Tech Will Dictate Future Law Firm Success

    Author Photo

    Law firms need to shift their focus from solving the needs of their lawyers with siloed solutions to implementing collaboration technology, thereby enabling more seamless workflows and team experiences amid widespread embrace of hybrid and remote work models, says Kate Jasaitis at HBR Consulting.

  • How To Effectively Prepare A Witness For Remote Testimony

    Author Photo

    Many of the lessons taught in an introductory theater performance class can provide foundational guidelines for virtual witness preparation, including the importance of props, proper lighting and wardrobe decisions, and of acknowledging that the star of your show is not a Zoom expert, say Hailey Drescher at Trask Consulting and Michael Thomas at Foley & Lardner.

  • A Crucial Element In Patent Prosecution: Examiner Experience

    Author Photo

    Michael Sartori at Baker Botts analyzed pending applications at the U.S. Patent and Trademark Office and found that examiner experience often affects the prosecution and outcome of a patent application, and knowing the examiner's experience, status and type can help in forming prosecution strategies to move an application to allowance.

  • As Cyber Risks Surge, Remember Attorneys' Ethical Duties

    Author Photo

    The prevalence of remote work and a greater threat of Russian cyberattacks should serve as a stark reminder of a lawyer's professional obligations to guard against unauthorized disclosure of client information and to protect client interests in the event of a cyberattack, says Alvin Mathews at Ulmer & Berne.

  • Rethinking E-Discovery Readiness Amid Rise Of Collab Tools

    Author Photo

    Online collaboration platforms and instant messaging tools are quickly becoming the primary mode of internal business communications, leading to disputes around discoverability of data on these platforms and underscoring the need for new preservation processes to ensure compliance with discovery obligations, say Jay Carle and Ryan Tilot at Seyfarth.

  • Health Cos. Could See More Conference Enforcement Risk

    Author Photo

    As medical conferences return in person after a two-year hiatus, government agencies show signs of increased enforcement interest, and health companies' staff training may have faded, heightening the importance of renewed risk management, says Mary Kohler at Kohler Health.

  • Series

    Embracing ESG: Uber Counsel Talks Safety Standards

    Author Photo

    Katie Waitzman at Uber discusses how in-house counsel can use environmental, social and corporate governance principles to bridge risk and innovation, as exemplified by the company’s recent women’s safety initiatives.

  • Opinion

    Prospectively Appointing Jackson To High Court Is Unlawful

    Author Photo

    President Joe Biden should rescind his prospective appointment of Judge Ketanji Brown Jackson to the U.S. Supreme Court as the decision contradicts the court's reasoning in Marbury v. Madison, raises gravely troubling issues regarding presidential discretion and brings a serious question about her legitimacy as a justice, says attorney John Reeves.

  • Strategies To Help Close IP Law's Long-Standing Gender Gap

    Author Photo

    While women comprise 37% of licensed attorneys, they represent just 17% of patent attorneys, and awareness by corporations and law firms of this kind of statistical information, along with incentives and transparency, can help bring about meaningful change, say Irene Liu at Hopin, Robin Preble at Target and Megan Redmond at Erise IP.

  • Opinion

    Big Cos. Shouldn't Cry 'Settlement Pressure' To Justify Appeal

    Author Photo

    The Sixth Circuit was correct to find that intense pressure to settle doesn't earn opioid case defendants Walgreens and Walmart an interlocutory appeal or new trial on liability, as that argument applies only when a defendant is risk averse, a notion not suited to large public corporations, says J.B. Heaton at One Hat Research.

  • The Rise Of Cannabis Mobile Commerce

    Author Photo

    As mobile commerce proliferates around the globe, cannabis companies will likely increase development of smartphone applications for sales and delivery — once they are able to overcome the unique challenges posed by payment processing barriers and the hodgepodge of state regulations, say Zachary Kobrin and Jonathan Robbins at Akerman.

  • Perspectives

    Time To Fix Legal Industry's Environmental Pro Bono Problem

    Author Photo

    As we observe Earth Month, it's sobering to note that pro bono environmental law work lags behind other practice areas — but the good news is that there are numerous organizations that can help lawyers get connected with environment-related pro bono projects, says Matthew Karmel at Riker Danzig.

  • Patent Strategy Considerations After Caltech Estoppel Ruling

    Author Photo

    The Federal Circuit's recent Caltech v. Broadcom decision, its errata and subsequent case law applying inter partes review estoppel highlight the need for thorough due diligence and precise development of litigation strategy before deciding to enforce or invalidate certain patents, say attorneys at Goldberg Segalla.

  • Changes To Watch In China's Human Genetic Resources Regs

    Author Photo

    While China’s recently published draft implementation rules on the administration of human genetic resources ease certain requirements, multinational pharmaceutical companies should adjust their compliance for reporting and law enforcement provisions that may present greater challenges, say attorneys at Tian Yuan.

  • Opinion

    SG Must Take A Stand On Medical Cannabis Reimbursement

    Author Photo

    The solicitor general's expected brief in Musta v. Mendota Heights Dental Center — on whether the U.S. Supreme Court should resolve how federal drug laws affect state laws requiring workers’ compensation benefits for medical marijuana treatment — will need to make a clear recommendation, because the cannabis industry can no longer tolerate half measures, says David Standa at Greenspoon Marder.

Want to publish in Law360?


Submit an idea
Can't find the article you're looking for? Click here to search the Life Sciences archive.
Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!